Literature DB >> 15897157

Association of apolipoprotein J-positive beta-amyloid plaques with dystrophic neurites in Alzheimer's disease brain.

M D Martin-Rehrmann1, H-S Hoe, E M Capuani, G W Rebeck.   

Abstract

Apolipoprotein J (apoJ), also known as clusterin and SP-40,40, binds soluble beta-amyloid (Abeta and is up-regulated in the Alzheimer's disease (AD) brain. In the present study we classified apoJ-immunopositive Abeta deposits in AD temporal cortex, and found apoJ-immunoreactive plaques were often associated with dystrophic neurites. Quantitative immunohistochemical analysis of five AD brains showed that 29% of Abeta deposited in the parenchyma was associated with apoJ. Of Abeta deposits with apoJ immunopositivity, 71% were associated with phospho-tau-positive dystrophic neurites in the surrounding tissue. Conversely, 64% of phospho-tau-labeled neuritic deposits were labeled with apoJ. ApoJ was found at the core of these deposits, and co-localized with the amyloid staining agent thioflavine-S. To test the direct effects of apoJ on tau metabolism, we treated cells in culture with apoJ-containing conditioned media, and we injected apoJ-containing media into the rat hippocampus. Using both systems, we observed increases in levels of tau and phosphorylated tau. Our findings demonstrate that apoJ immunopositivity strongly correlates with the presence of amyloid and associated neuritic dystrophy in the neuropil of AD temporal cortex, and supports a model where extracellular apoJ facilitates the conversion of diffuse Abeta deposits into amyloid and enhances tau phosphorylation in neurites surrounding these of plaques.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897157     DOI: 10.1007/bf03036452

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  38 in total

1.  Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide.

Authors:  S M Hammad; S Ranganathan; E Loukinova; W O Twal; W S Argraves
Journal:  J Biol Chem       Date:  1997-07-25       Impact factor: 5.157

Review 2.  The Alzheimer family of diseases: many etiologies, one pathogenesis?

Authors:  J Hardy
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

3.  Possible neuroprotective role of clusterin in Alzheimer's disease: a quantitative immunocytochemical study.

Authors:  P Giannakopoulos; E Kövari; L E French; I Viard; P R Hof; C Bouras
Journal:  Acta Neuropathol       Date:  1998-04       Impact factor: 17.088

4.  Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation.

Authors:  H S Cho; B T Hyman; S M Greenberg; G W Rebeck
Journal:  J Neuropathol Exp Neurol       Date:  2001-04       Impact factor: 3.685

5.  Correlations of synaptic and pathological markers with cognition of the elderly.

Authors:  D W Dickson; H A Crystal; C Bevona; W Honer; I Vincent; P Davies
Journal:  Neurobiol Aging       Date:  1995 May-Jun       Impact factor: 4.673

6.  Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.

Authors:  S E Stoltzner; T J Grenfell; C Mori; K E Wisniewski; T M Wisniewski; D J Selkoe; C A Lemere
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

7.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

8.  Characterization of apolipoprotein J-Alzheimer's A beta interaction.

Authors:  E Matsubara; B Frangione; J Ghiso
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

9.  Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies.

Authors:  Kensuke Sasaki; Katsumi Doh-ura; Yoshinobu Wakisaka; Toru Iwaki
Journal:  Acta Neuropathol       Date:  2002-05-09       Impact factor: 17.088

10.  Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease.

Authors:  T Gomez-Isla; H L West; G W Rebeck; S D Harr; J H Growdon; J J Locascio; T T Perls; L A Lipsitz; B T Hyman
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

View more
  15 in total

Review 1.  Neurotoxins and neurotoxicity mechanisms. An overview.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

2.  Plasma Amyloid-Beta Levels in Patients with Different Types of Cancer.

Authors:  Wang-Sheng Jin; Xian-Le Bu; Yu-Hui Liu; Lin-Lin Shen; Zhen-Qian Zhuang; Shu-Sheng Jiao; Chi Zhu; Qing-Hua Wang; Hua-Dong Zhou; Tao Zhang; Yan-Jiang Wang
Journal:  Neurotox Res       Date:  2016-12-03       Impact factor: 3.911

Review 3.  Exploring the Role of CLU in the Pathogenesis of Alzheimer's Disease.

Authors:  Md Sahab Uddin; Md Tanvir Kabir; Mst Marium Begum; Md Siddiqul Islam; Tapan Behl; Ghulam Md Ashraf
Journal:  Neurotox Res       Date:  2020-08-21       Impact factor: 3.911

4.  Identifying candidate genes and drug targets for Alzheimer's disease by an integrative network approach using genetic and brain region-specific proteomic data.

Authors:  Andi Liu; Astrid M Manuel; Yulin Dai; Brisa S Fernandes; Nitesh Enduru; Peilin Jia; Zhongming Zhao
Journal:  Hum Mol Genet       Date:  2022-09-29       Impact factor: 5.121

Review 5.  Neuropathology of Alzheimer's Disease.

Authors:  Jorge A Trejo-Lopez; Anthony T Yachnis; Stefan Prokop
Journal:  Neurotherapeutics       Date:  2021-11-02       Impact factor: 6.088

Review 6.  Siglec receptors and hiding plaques in Alzheimer's disease.

Authors:  Antero Salminen; Kai Kaarniranta
Journal:  J Mol Med (Berl)       Date:  2009-04-24       Impact factor: 4.599

7.  Cytosolic proteins lose solubility as amyloid deposits in a transgenic mouse model of Alzheimer-type amyloidosis.

Authors:  Guilian Xu; Stanley M Stevens; Brenda D Moore; Scott McClung; David R Borchelt
Journal:  Hum Mol Genet       Date:  2013-03-19       Impact factor: 6.150

8.  Association between clusterin gene polymorphism rs11136000 and late-onset Alzheimer's disease susceptibility: A review and meta-analysis of case-control studies.

Authors:  Wenjin Du; Jiping Tan; Wei Xu; Jinwen Chen; Luning Wang
Journal:  Exp Ther Med       Date:  2016-09-21       Impact factor: 2.447

9.  Single Nucleotide Polymorphism rs11136000 of CLU Gene (Clusterin, ApoJ) and the Risk of Late-Onset Alzheimer's Disease in a Central European Population.

Authors:  Vladimir J Balcar; Tomáš Zeman; Vladimír Janout; Jana Janoutová; Jan Lochman; Omar Šerý
Journal:  Neurochem Res       Date:  2020-11-18       Impact factor: 3.996

10.  Proteolytically inactive insulin-degrading enzyme inhibits amyloid formation yielding non-neurotoxic aβ peptide aggregates.

Authors:  Matias B de Tullio; Valeria Castelletto; Ian W Hamley; Pamela V Martino Adami; Laura Morelli; Eduardo M Castaño
Journal:  PLoS One       Date:  2013-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.